Whether you are a new T1D Family, a TrialNet participant, a healthcare provider, or a researcher — you'll find resources here.
We’re here to help you after a new T1D diagnosis. Get answers to frequently asked questions and learn about clinical studies testing ways to maintain insulin production.
While you wait for screening results, get answers to your questions, find out about next steps, and learn more about TrialNet’s Pathway to Prevention.
Your T1D families are important to you. Learn how easy it is to connect your patients with world-class T1D research.
The Hospital for Sick Children (SickKids) is one of twenty-five type 1 diabetes TrialNet International Clinical Centres at the forefront of type 1 diabetes research. Led by Diane Wherrett, MD, the TrialNet team at SickKids is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.
Alberta Childrens Hospital
2888 Shaganappi Trail NW, Calgary, AB T3B 6A8
Stollery Children's Hospital - Alberta Health Services
Edmonton Clinic Health Academy (ECHA), 11405-87 Avenue, Edmonton, AB T6G 1C9
IWK Health Center
5850/5980 University Ave, Halifax, NS B3K 6R8
Hamilton Health Sciences
McMaster Children's Hospital - Pediatric Lipid Clinic, Hamilton, ON L8N 3Z5
University of Western Ontario
339 Windermere Road, Rm. 60F11, London, ON N6A5A5
Childrens Hospital of Eastern Ontario
401 Smyth Road, Ottawa, ON K1H8L1
Royal University Hospital
103 Hospital Drive, Saskatoon, SK S7N 0W8
The Janeway Child Health and Rehabilitation Centre
300 Prince Phillip Dr., St. John's, NL A1B 3V6
University of British Columbia
4480 Oak Street, Vancouver, BC V6H 3V4
University of Manitoba
510-715 McDermot Ave., Winnipeg, MB R3E 2P4
If you have a relative with T1D, you’re in a unique position to help us learn more about the disease and how to stop it. The first step is to sign up for Pathway to Prevention screening to determine your risk of developing T1D.
TrialNet is testing the drug abatacept to see if it can delay or prevent progression of early stage T1D (stage 1 to stage 2) and ultimately prevent clinical diagnosis (stage 3). In earlier studies for people newly diagnosed (stage 3), abatacept helped slow down disease progression.
We tested the drug teplizumab to see if it could delay or prevent progression of early stage T1D (stage 2) and prevent clinical diagnosis (stage 3). In earlier studies in people newly diagnosed (stage 3), teplizumab helped to prolong insulin production.
Once your study ends, we're still here for you. Participant monitoring and continued involvement helps us learn more about T1D.